Tuberculosis (TB) is a chronic disease caused byMycobacterium tuberculosis (Mtb), which shows a long
treatment cycle often leads to drug resistance, making treatment more
difficult. Immunogens present in the pathogen’s cell membrane
can stimulate endogenous immune responses. Therefore, an effective
lipid-based vaccine or drug delivery vehicle formulated from the pathogen’s
cell membrane can improve treatment outcomes. Herein, we extracted
and characterized lipids fromMycobacterium smegmatis, and the extracts contained lipids belonging to numerous lipid classes
and compounds typically found associated with mycobacteria. The extracted
lipids were used to formulate biomimetic lipid reconstituted nanoparticles
(LrNs) and LrNs-coated poly(lactic-co-glycolic acid)
nanoparticles (PLGA-LrNs). Physiochemical characterization and results
of morphology suggested that PLGA-LrNs exhibited enhanced stability
compared with LrNs. And both of these two types of nanoparticles inhibited
the growth of M. smegmatis. After loading
different drugs, PLGA-LrNs containing berberine or coptisine strongly
and synergistically prevented the growth of M. smegmatis. Altogether, the bacterial membrane lipids we extracted with antibacterial
activity can be used as nanocarrier coating for synergistic antibacterial
treatment of M. smegmatisan
alternative model of Mtb, which is expected as a novel therapeutic
system for TB treatment.